Enhancing Oxygen,
Fueling Life
Targeting Treatments for Hypoxia
Learn more

Improving Oxygen Availability

Novel Mechanism of Action

Lead drug candidate Trans sodium crocetinate (TSC) enhances the oxygen diffusion process, supporting normal, physiologic levels of oxygen diffusion at uptake and delivery.

Selective for Hypoxic Tissue

In animal models, TSC’s mechanism of action enhanced oxygen availability to hypoxic tissue without oversupplying normoxic tissue.

Demonstrated Safety Profile

TSC has been safe and well tolerated in over 200 subjects dosed in prior preclinical and clinical studies.

OUR TECHNOLOGY

Lead drug
candidate, Trans sodium
crocetinate (TSC)

We are developing our lead product, TSC, to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions.

Learn more

News

Latest press releases, announcements, and more.

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

 Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial 150 150 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., May 23, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer

 Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., May 18, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

 Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

 Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements

 Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan

 Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., April 18, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Completes Dosing in Altitude Trial

 Diffusion Pharmaceuticals Completes Dosing in Altitude Trial 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., April 11, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders

 Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., April 08, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update

 Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., March 21, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts

 Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Feb. 24, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

News Releases

Podcasts

Fueling Life, a podcast from Diffusion Pharmaceuticals.

Episode 4: Analyzing TSC’s Impact on Carbon Monoxide Diffusion Through the Lungs
 Episode 4: Analyzing TSC’s Impact on Carbon Monoxide Diffusion Through the Lungs 150 150 Diffusion Pharmaceuticals Inc.

Diffusion’s Chief Medical Officer Dr. Chris Galloway provides an overview of the ILD-DLCO Trial, the third in a trio of Oxygenation Trials that will inform late-phase programs and clinical indications for lead drug candidate TSC.

Episode 3: Evaluating the Effects of TSC on Maximal Oxygen Consumption
 Episode 3: Evaluating the Effects of TSC on Maximal Oxygen Consumption 150 150 Diffusion Pharmaceuticals Inc.

Chief Medical Officer Dr. Chris Galloway previews Diffusion’s Altitude Trial, the second in a trio of Oxygenation Trials that will collectively inform late phase programs and the clinical development plan for lead drug candidate TSC.

Episode 2: Exploring TSC’s Impact on Tissue-Level Changes in Oxygen
 Episode 2: Exploring TSC’s Impact on Tissue-Level Changes in Oxygen 150 150 Diffusion Pharmaceuticals Inc.

Dr. Chris Galloway, Chief Medical Officer of Diffusion, explains the TCOM Trial design, top-line results, and the relevancy of this first of three Oxygenation Trials that together will inform late-phase programs and clinical indications for lead drug candidate TSC.

Episode 1: The Science of Solving for Hypoxia
 Episode 1: The Science of Solving for Hypoxia 150 150 Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals CEO Robert Cobuzzi, Jr., PhD discusses cellular oxygen deficiency, the TSC development plan, and potential future applications for this small molecule therapeutic with a novel MOA.

Introducing Fueling Life: a Podcast from Diffusion Pharmaceuticals
 Introducing Fueling Life: a Podcast from Diffusion Pharmaceuticals 150 150 Diffusion Pharmaceuticals Inc.

This podcast will discuss hypoxia, a potentially fatal shortage of oxygen in a body tissue, and cover the development plan for lead product candidate TSC, which enhances oxygen diffusion to hypoxic tissue.

Listen on Spotify

Back to top